Cargando…

The cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial

BACKGROUND: The objective of this article is to describe the design of a study to evaluate the clinical and economic effects of a Disease Management model on functional health, quality of care and quality of life of persons living in homes for the elderly. METHODS: This study concerns a cluster rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Boorsma, Marijke, van Hout, Hein PJ, Frijters, Dinnus H, Ribbe, Miel W, Nijpels, Giel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2488343/
https://www.ncbi.nlm.nih.gov/pubmed/18606020
http://dx.doi.org/10.1186/1472-6963-8-143
_version_ 1782158119963459584
author Boorsma, Marijke
van Hout, Hein PJ
Frijters, Dinnus H
Ribbe, Miel W
Nijpels, Giel
author_facet Boorsma, Marijke
van Hout, Hein PJ
Frijters, Dinnus H
Ribbe, Miel W
Nijpels, Giel
author_sort Boorsma, Marijke
collection PubMed
description BACKGROUND: The objective of this article is to describe the design of a study to evaluate the clinical and economic effects of a Disease Management model on functional health, quality of care and quality of life of persons living in homes for the elderly. METHODS: This study concerns a cluster randomized controlled clinical trial among five intervention homes and five usual care homes in the North-West of the Netherlands with a total of over 500 residents. All persons who are not terminally ill, are able to be interviewed and sign informed consent are included. For cognitively impaired persons family proxies will be approached to provide outcome information. The Disease Management Model consists of several elements: (1) Trained staff carries out a multidimensional assessment of the patients functional health and care needs with the interRAI Long Term Care Facilities instrument (LTCF). Computerization of the LTCF produces immediate identification of problem areas and thereby guides individualized care planning. (2) The assessment outcomes are discussed in a Multidisciplinary Meeting (MM) with the nurse, primary care physician, nursing home physician and Psychotherapist and if necessary other members of the care team. The MM presents individualized care plans to manage or treat modifiable disabilities and risk factors. (3) Consultation by an nursing home physician and psychotherapist is offered to the frailest residents at risk for nursing home admission (according to the interRAI LTCF). Outcome measures are Quality of Care indicators (LTCF based), Quality Adjusted Life Years (Euroqol), Functional health (SF12, COOP-WONCA), Disability (GARS), Patients care satisfaction (QUOTE), hospital and nursing home days and mortality, health care utilization and costs. DISCUSSION: This design is unique because no earlier studies were performed to evaluate the effects and costs of this Disease Management Model for disabled persons in homes for the elderly on functional health and quality of care. TRAIL REGISTRATION NUMBER: ISRCTN11076857
format Text
id pubmed-2488343
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24883432008-07-29 The cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial Boorsma, Marijke van Hout, Hein PJ Frijters, Dinnus H Ribbe, Miel W Nijpels, Giel BMC Health Serv Res Study Protocol BACKGROUND: The objective of this article is to describe the design of a study to evaluate the clinical and economic effects of a Disease Management model on functional health, quality of care and quality of life of persons living in homes for the elderly. METHODS: This study concerns a cluster randomized controlled clinical trial among five intervention homes and five usual care homes in the North-West of the Netherlands with a total of over 500 residents. All persons who are not terminally ill, are able to be interviewed and sign informed consent are included. For cognitively impaired persons family proxies will be approached to provide outcome information. The Disease Management Model consists of several elements: (1) Trained staff carries out a multidimensional assessment of the patients functional health and care needs with the interRAI Long Term Care Facilities instrument (LTCF). Computerization of the LTCF produces immediate identification of problem areas and thereby guides individualized care planning. (2) The assessment outcomes are discussed in a Multidisciplinary Meeting (MM) with the nurse, primary care physician, nursing home physician and Psychotherapist and if necessary other members of the care team. The MM presents individualized care plans to manage or treat modifiable disabilities and risk factors. (3) Consultation by an nursing home physician and psychotherapist is offered to the frailest residents at risk for nursing home admission (according to the interRAI LTCF). Outcome measures are Quality of Care indicators (LTCF based), Quality Adjusted Life Years (Euroqol), Functional health (SF12, COOP-WONCA), Disability (GARS), Patients care satisfaction (QUOTE), hospital and nursing home days and mortality, health care utilization and costs. DISCUSSION: This design is unique because no earlier studies were performed to evaluate the effects and costs of this Disease Management Model for disabled persons in homes for the elderly on functional health and quality of care. TRAIL REGISTRATION NUMBER: ISRCTN11076857 BioMed Central 2008-07-07 /pmc/articles/PMC2488343/ /pubmed/18606020 http://dx.doi.org/10.1186/1472-6963-8-143 Text en Copyright © 2008 Boorsma et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Boorsma, Marijke
van Hout, Hein PJ
Frijters, Dinnus H
Ribbe, Miel W
Nijpels, Giel
The cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial
title The cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial
title_full The cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial
title_fullStr The cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial
title_full_unstemmed The cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial
title_short The cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial
title_sort cost-effectiveness of a new disease management model for frail elderly living in homes for the elderly, design of a cluster randomized controlled clinical trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2488343/
https://www.ncbi.nlm.nih.gov/pubmed/18606020
http://dx.doi.org/10.1186/1472-6963-8-143
work_keys_str_mv AT boorsmamarijke thecosteffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT vanhoutheinpj thecosteffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT frijtersdinnush thecosteffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT ribbemielw thecosteffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT nijpelsgiel thecosteffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT boorsmamarijke costeffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT vanhoutheinpj costeffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT frijtersdinnush costeffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT ribbemielw costeffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial
AT nijpelsgiel costeffectivenessofanewdiseasemanagementmodelforfrailelderlylivinginhomesfortheelderlydesignofaclusterrandomizedcontrolledclinicaltrial